FirmAtlas
Company handbook · TECH · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-16
TECH · CIK 842023 · LATEST FILING: 10-K FY26 · FILED AUG 24, 2026
BIO-TECHNE Corp
$72.57
+0.05 (+0.07%)
Close, Oct 16, 2026 · 52-week $43–73
Last fiscal year
BIO-TECHNE Corp reported revenue of $1.2B for the year ended Jun 30, 2026 (FY26), down 0.4% from FY25. Net income was $182M, operating cash flow $292M and free cash flow $263M. Source: 10-K filed Aug 24, 2026.
Market cap
$11.3B
P/E
62.3
EV/EBITDA
32.2x
P/B
5.4
Div yield
0.44%
ROIC
9.2%
Revenue 1Y
−0.4%/yr
EPS 1Y
152.2%/yr
Shares 1Y
+0.7%
Loading chart…
Median
Daily closes, split-adjusted · ratios at each fiscal year end
Company
CEOKim Kelderman
HQMinneapolis, MN
AuditorKPMG LLP
Employees3,000
Year endsJune
Revenue by segment · FY26
Protein Sciences72%
Diagnostics And Genomics28%
Compounded growth & averages
10Y
5Y
3Y
TTM
Share price
10.6%
−10.2%
1.9%
17.8%
Upgrade to see 10 years
Share price: yearly compound rate of the traded close; the last column is the past year.
Where the cash went · FY25–FY26
$478M deployed
Capex
$60M
12.5%
Dividends
$100M
21.0%
Buybacks
$317M
66.5%
Operating cash flow over the period: $580M. Total debt changed by −$146M. R&D of $194M is already inside operating costs.
More cash than debt at the end of FY26.
Growth engines
How much of the profit growth came from new investment, and how much from running the business better.
Upgrade to see 10 years
Financials
Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · FY26 = year ended Jun 30, 2026 · change vs previous year
Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier
Per-share figures are split-adjusted (4-for-1 split after FY21).
Income
Revenue
1,220
1,215−0.4%
YoY
−0.4%
Gross profit
790
799+1.1%
Gross margin
64.8%
65.8%+1.0 pp
Operating income
102
252+146.3%
Operating margin
8.4%
20.7%+12.3 pp
EBITDA
212
349+64.6%
EBITDA margin
17.4%
28.7%+11.3 pp
Interest expense
9
10+13.2%
Interest coverage
24.93x
36.27x+11.33x
Net income
73
182+147.7%
YoY
+147.7%
Net margin
6.0%
15.0%+8.9 pp
EPS (diluted, $)
0.46
1.16+152.2%
YoY
+152.2%
Balance sheet
Total assets
2,558
2,587+1.1%
Cash & short-term investments
162
265+63.2%
Accounts receivable
207
217+4.7%
Inventory
189
196+3.3%
Net PP&E
246
232−5.6%
Other assets
1,754
1,678−4.3%
Total liabilities
639
479−25.1%
Accounts payable
25
27+5.5%
Total debt
346
200−42.2%
Other liabilities
268
252−6.0%
Shareholders’ equity
1,919
2,108+9.9%
Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.
Cash flow statement · as filed
Cash from operations
288
292+1.6%
Net income
73
182+147.8%
Depreciation & amortization
110
97−11.4%
Stock-based compensation
41
41+1.3%
Working capital & other
63
(29)−145.0%
Cash from investing
(35)
(18)n/m
Capex
(31)
(29)n/m
Other investing
(4)
11n/m
Cash from financing
(254)
(169)n/m
Dividends
(50)
(50)n/m
Buybacks
(276)
(42)n/m
Shares issued
52
81+55.8%
Other financing
20
(158)−872.2%
Net change in cash
10
103+886.3%
Free cash flow (OCF − capex)
257
263+2.6%
Where the cash went
Operating cash flow
288
292+1.6%
Reinvested in the business
31
29−7.0%
% of operating cash flow
10.8%
9.9%
Capex
31
29−7.0%
R&D (memo, already in costs)
99
95−4.8%
Free cash flow
257
263+2.6%
YoY
+2.6%
Returned to shareholders
326
92−71.9%
% of free cash flow
127.1%
34.8%
Dividends
50
50−0.9%
Buybacks
276
42−84.9%
Change in total debt
—
(146)
Cash left over
—
26
FCF conversion (FCF ÷ net income)
349.5%
144.8%−204.8 pp
Owner earnings
—
236
Owner earnings margin
—
19.4%
Buyback yield
3.5%
0.4%−3.1 pp
Returns & ratios
ROIC (all capital)
3.6%
9.2%+5.6 pp
ROIC (operating)
12.4%
30.8%+18.5 pp
Net debt / EBITDA
0.87x
−0.19x−1.05x
Debt / equity
0.18x
0.09x−0.09x
Cash conversion cycle (days)
201
213+12 d
ROE
3.8%
8.6%+4.8 pp
ROA
2.9%
7.0%+4.2 pp
ROCE
4.3%
10.4%+6.1 pp
NOPAT
76
190+149.7%
Invested capital (operating)
617
617+0.1%
Invested capital (all)
2,103
2,044−2.8%
Reinvestment rate
—
0.4%
Debtor days
62
65+3 d
Inventory days
161
172+11 d
Days payable
22
23+2 d
Income
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
287
296
311
321
vs year-ago quarter
Gross profit
188
191
208
211
Gross margin
65.6%
64.6%
66.9%
65.8%
Operating income
48
54
75
74
Net income
38
38
51
55
vs year-ago quarter
Net margin
13.3%
12.8%
16.4%
17.0%
EPS (diluted, $)
0.24
0.24
0.32
0.35
vs year-ago quarter
Balance sheet
Sep '25
Dec '25
Mar '26
Jun '26
Total assets
2,526
2,523
2,551
2,587
Cash & equivalents
145
173
210
265
Total debt
300
260
200
200
Shareholders’ equity
1,966
2,011
2,085
2,108
Cash flow
Sep '25
Dec '25
Mar '26
Jun '26
Operating cash flow
28
82
87
95
Capex
5
6
9
8
Free cash flow
22
76
78
87
vs year-ago quarter